NRXBF (NurExone Biologic) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

NurExone Biologic's Capital Expenditure for the three months ended in Dec. 2024 was $-0.05 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-1.48 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

NurExone Biologic Capex-to-Operating-Income Historical Data

The historical data trend for NurExone Biologic's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Capex-to-Operating-Income Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Capex-to-Operating-Income

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Capex-to-Operating-Income	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of NurExone Biologic's Capex-to-Operating-Income

For the Biotechnology subindustry, NurExone Biologic's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Capex-to-Operating-Income falls into.

Save Embed

;

Save Embed

;

NurExone Biologic Capex-to-Operating-Income Calculation

NurExone Biologic's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.649)	/	-5.009
	=	N/A

NurExone Biologic's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.046)	/	-1.484
	=	N/A

NurExone Biologic (OTCPK:NRXBF) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

NurExone Biologic Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

J90:Germany NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.